|
Clinical trials start for ABI's breath asthma check rapid assay
Stock Market Wire StockMarketWire.com – Clinical trials for Akers Biosciences' breath asthma check rapid assay have begun in Clearwater, Florida. The trials have been designed to provide the clinical information to be included in a submission for regulatory approvals … 18 APRIL 2011 Akers Biosciences* AKR (FTSE AIM All Share) 4p BUY (TP-10p) |
View full post on asthma – Google News